Unraveling Diabetes: A New Perspective in Africa and Beyond

Research reveals a unique form of type 1 diabetes among African populations, characterized by absent autoantibodies and low genetic risk, challenging existing diagnostic and treatment norms. In related news, J&J's Tremfya shows promise against Crohn’s disease, outperforming existing treatments by achieving higher remission rates without long-term steroid use.

A groundbreaking discovery could transform the diagnosis and management of type 1 diabetes in African populations, researchers report. Traditionally linked to an autoimmune attack on insulin-producing cells, a study of 894 youths in Cameroon, Uganda, and South Africa challenges these assumptions. Surprisingly, 65% lacked typical autoantibodies or genetic predispositions associated with the disease.

Comparative analysis with U.S. data highlights that 15% of Black Americans with type 1 diabetes share similar non-autoimmune characteristics, differing from the largely autoimmune-driven cases in white populations, according to The Lancet Diabetes and Endocrinology.

In parallel development, a psoriasis drug shows new potential for Crohn’s disease. Johnson & Johnson’s Tremfya outperformed Stelara in trials with 1,021 patients, demonstrating higher remission rates. The findings, published in The Lancet, underscore Tremfya’s ability to induce remission without steroids, promising fewer complications and hospitalizations.